Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt 0.21
MNKD's Cash to Debt is ranked lower than
51% of the 900 Companies
in the Global Biotechnology industry.

( Industry Median: 83.08 vs. MNKD: 0.21 )
MNKD' s 10-Year Cash to Debt Range
Min: 0   Max: No Debt
Current: 0.21

F-Score: 4
Z-Score: -7.61
M-Score: -0.61
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
ROA (%) -74.04
MNKD's ROA (%) is ranked higher than
56% of the 889 Companies
in the Global Biotechnology industry.

( Industry Median: -17.36 vs. MNKD: -74.04 )
MNKD' s 10-Year ROA (%) Range
Min: -196.87   Max: -42.71
Current: -74.04

-196.87
-42.71
ROC (Joel Greenblatt) (%) -95.95
MNKD's ROC (Joel Greenblatt) (%) is ranked higher than
75% of the 861 Companies
in the Global Biotechnology industry.

( Industry Median: -243.56 vs. MNKD: -95.95 )
MNKD' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -285.33   Max: -72.81
Current: -95.95

-285.33
-72.81
EBITDA Growth (%) -27.20
MNKD's EBITDA Growth (%) is ranked higher than
61% of the 598 Companies
in the Global Biotechnology industry.

( Industry Median: -10.50 vs. MNKD: -27.20 )
MNKD' s 10-Year EBITDA Growth (%) Range
Min: -43   Max: 10.9
Current: -27.2

-43
10.9
EPS Growth (%) -24.70
MNKD's EPS Growth (%) is ranked higher than
67% of the 630 Companies
in the Global Biotechnology industry.

( Industry Median: -12.60 vs. MNKD: -24.70 )
MNKD' s 10-Year EPS Growth (%) Range
Min: -42.9   Max: 7.6
Current: -24.7

-42.9
7.6
» MNKD's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2013

MNKD Guru Trades in Q2 2013

Steven Cohen 212,767 sh (New)
Jim Simons Sold Out
» More
Q3 2013

MNKD Guru Trades in Q3 2013

Murray Stahl 57,451 sh (New)
Steven Cohen 231,900 sh (+8.99%)
» More
Q4 2013

MNKD Guru Trades in Q4 2013

Murray Stahl 106,211 sh (+84.87%)
Steven Cohen 143,117 sh (-38.29%)
» More
Q1 2014

MNKD Guru Trades in Q1 2014

Murray Stahl 134,495 sh (+26.63%)
Steven Cohen 103,800 sh (-27.47%)
» More
» Details

Insider Trades

Latest Guru Trades with MNKD

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Jean-Marie Eveillard 2013-03-31 Sold Out 0.01%$2.31 - $3.56 $ 8.78219%0
Jean-Marie Eveillard 2012-12-31 New Buy0.01%$1.85 - $2.83 $ 8.78306%800000
Premium More recent guru trades are included for Premium Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 168.80
MNKD's P/B is ranked higher than
55% of the 956 Companies
in the Global Biotechnology industry.

( Industry Median: 5.51 vs. MNKD: 168.80 )
MNKD' s 10-Year P/B Range
Min: 0   Max: 219.8
Current: 168.8

0
219.8
EV-to-EBIT -22.95
MNKD's EV-to-EBIT is ranked higher than
50% of the 956 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. MNKD: -22.95 )
MNKD' s 10-Year EV-to-EBIT Range
Min: 0   Max: 0
Current: -22.95

Current Ratio 0.89
MNKD's Current Ratio is ranked higher than
50% of the 892 Companies
in the Global Biotechnology industry.

( Industry Median: 4.02 vs. MNKD: 0.89 )
MNKD' s 10-Year Current Ratio Range
Min: 0.12   Max: 12.24
Current: 0.89

0.12
12.24
Quick Ratio 0.89
MNKD's Quick Ratio is ranked higher than
52% of the 892 Companies
in the Global Biotechnology industry.

( Industry Median: 3.74 vs. MNKD: 0.89 )
MNKD' s 10-Year Quick Ratio Range
Min: 0.12   Max: 12.24
Current: 0.89

0.12
12.24

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 180.00
MNKD's Price/Tangible Book is ranked higher than
59% of the 956 Companies
in the Global Biotechnology industry.

( Industry Median: 8.78 vs. MNKD: 180.00 )
MNKD' s 10-Year Price/Tangible Book Range
Min: 1.35   Max: 80.4
Current: 180

1.35
80.4
Forward Rate of Return (Yacktman) -35.94
MNKD's Forward Rate of Return (Yacktman) is ranked higher than
64% of the 738 Companies
in the Global Biotechnology industry.

( Industry Median: -10.54 vs. MNKD: -35.94 )
MNKD' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -2.7   Max: 54
Current: -35.94

-2.7
54

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:NNF1.Germany
MannKind Corporation, a development stage biopharmaceutical company, was founded in 1991. The Company is engaged in the discovery, development and commercialization of therapeutic products for diseases such as diabetes. Its product candidate, AFREZZA inhalation powder, is an ultra insulin therapy that is in late-stage clinical investigation for the treatment of adults with type 1 or type 2 diabetes for the control of hyperglycemia. The Company also develops MKC1106-MT, an investigational cancer immunotherapy product, which is in Phase II clinical trials; and MKC204, which is in preclinical development stage for the treatment of malignancies and inflammatory diseases.
» More Articles for MNKD

Headlines

Articles On GuruFocus.com
Mannkind Corporation: Safe Labeling, Incentivized Spirometry and Experts Votes of Confidence Jul 25 2014 
MannKind Corporation: Investors Should Seek Truth As The Requisite To Finding This Alpha Jul 24 2014 
Recent Tsunami of Insider Shares Purchased: A Prelude To Mannkind Partnership or Acquisition Jul 19 2014 
Mannkind Corporation: Why Afrezza Would Completely Dominate The Insulin Market Jul 16 2014 
A Look at Mannkind Corporation's True Value Jul 02 2014 
Time to Gamble on MannKind’s Afrezza Mar 27 2014 
MannKind Corporation: Will It Make It to the Promised Land? Mar 17 2014 
Weekly CFO Buys Highlight: CPRX, APPY, MEI, MNKD Jul 09 2012 
These 4 Biotech Stocks Are a Buy Now Feb 08 2012 
The Details of the Afrezza Approval Delay Jan 31 2012 


More From Other Websites
MannKind: Why The Short Argument Is Shortsighted Jul 25 2014
MannKind Pharma Gets Hedge Fund Treatment, Traders Rally Defence Jul 25 2014
MannKind Afrezza Partnership News Coming Within Weeks Jul 25 2014
Hedge fund: This 'mania' health stock will fall 90% Jul 24 2014
MANNKIND CORP Files SEC form 8-K, Creation of a Direct Financial Obligation or an Obligation under... Jul 22 2014
Top Swing Trade Ideas for Monday July 21: Cliffs Natural Resources, MannKind, PolyOne Jul 21 2014
Fed Chair Yellen Says Small Biotech Stocks Over-Valued Jul 15 2014
MannKind: Are These Top Big Pharma Companies Potential Partners? Jul 14 2014
Biotech Stock Mailbag: MannKind, Bluebird, Northwest Bio, More '14 Tradable Biotech Events Jul 14 2014
MannKind (MNKD) Stock Continues to Decline Wednesday Jul 02 2014
MannKind Poll Points to Bias That Stock Will Rise Above $15 into 2015 Jul 02 2014
Time to take profits in MannKind, Barron's says Jul 01 2014
[$$] MannKind: Take the Money and Run Very Fast Jul 01 2014
MannKind Is Still a Risky Investment Even With FDA Approval Jul 01 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Email Hide